Introduction: Mesenchymal stem cells (MSCs) are immune evasive and can be transplanted to HLA-unmatched
allogeneic recipients. Animal studies indicated that transplantation of MSCs improved
the motor function in SCA 2 transgenic mice. This is a phase I/II clinical trial aiming
to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSCs) for
the treatment of cerebellar ataxia.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
